Drug Profile
INCB 47986
Alternative Names: INCB-47986; INCB047986Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Myelodysplastic syndromes; Rheumatoid arthritis
Most Recent Events
- 10 Feb 2015 Discontinued - Phase-I for Cancer in USA (PO)
- 01 Sep 2014 Discontinued - Phase-I/II for Myelodysplastic syndromes in USA (PO)
- 01 Aug 2014 Discontinued - Phase-II for Rheumatoid arthritis in USA (PO)